Compare Moderna, Inc. (MRNA) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Ross Stores, Inc. — how do they compare? Moderna, Inc. trades at $59.72 (market cap $23.60B), while Ross Stores, Inc. trades at $233.99 (market cap $75.63B). The key difference: Ross Stores, Inc. is far larger — about 3.2× Moderna, Inc.'s market cap, and Ross Stores, Inc. pays a 0.75% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | ROST | |
|---|---|---|
Market Cap | $23.60B | $75.63B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $240.13 |
52-Week Low | $22.36 | $134.02 |
Enterprise Value | $19.70B | $76.23B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Ross Stores (ROST) trades at $235.78, up 1.05% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q1 2026 results with 21% sales growth and expanding margins, while expanding its store footprint with 47 new locations in mid-2026. Valuation metrics show a P/E of 32.93 and robust profitability with a 38.98% ROE, though the stock trades near analyst price targets.
The outlook remains positive due to consistent earnings outperformance and store expansion, but risks include high valuation multiples and competitive retail pressures. Analyst consensus is bullish with a $259 price target, suggesting moderate upside potential from current levels amid broader market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
